The proposed bill, H.B. No. 2025-2026, seeks to enact section 124.826 of the Revised Code, which establishes a reimbursement program for state employees and elected officials for out-of-pocket costs associated with GLP-1 drugs, a class of medications approved for chronic weight management. The bill defines key terms such as "GLP-1 drug," "pharmacy," and "physician," and outlines the eligibility criteria for reimbursement. Specifically, it stipulates that reimbursements will cover costs incurred for GLP-1 drugs purchased through approved channels, with a maximum reimbursement of $500 per month during the first year and $250 during the second year of eligibility.

Additionally, the bill sets a limit on the duration of reimbursement applications to a maximum of 24 consecutive months, with provisions for reapplication after a six-month hiatus if certain weight criteria are met. The director of administrative services is tasked with determining eligibility and processing reimbursement applications, which must include proof of a qualifying body mass index and the amount paid for the GLP-1 drug. The bill also mandates the adoption of rules to implement these provisions, ensuring a structured approach to the reimbursement process.